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Abstract
Introduction Substantial preclinical evidence has indicated that
inhibition of integrin linked-kinase (ILK) correlates with cytotoxic/
cytostatic cellular effects, delayed tumor growth in animal
models of cancer, and inhibition of angiogenesis. Widely
anticipated to represent a very promising therapeutic target in
several cancer indications, it is increasingly evident that optimal
therapeutic benefits obtained using ILK targeting strategies will
only be achieved in combination settings. The purpose of this
study was to investigate the therapeutic potential of the ILK
small molecule inhibitor, QLT0267 (267), alone or in
combination with chemotherapies commonly used to treat
breast cancer patients.
Methods A single end-point metabolic assay was used as an
initial screen for 267 interactions with selected
chemotherapeutic agents. These in vitro assays were
completed with seven breast cancer cell lines including several
which over-expressed human epidermal growth factor receptor
2 (Her2). One agent, docetaxel (Dt), consistently produced
synergistic interactions when combined with 267. Dt/267
interactions were further characterized by measuring
therapeutic endpoints linked to phosphorylated protein kinase B
(P-AKT) suppression, inhibition of vascular endothelial growth
factor (VEGF) secretion and changes in cytoarchitecture. In vivo
efficacy studies were completed in mice bearing orthotopic
xenografts where tumor growth was assessed by
bioluminescence and calliper methods.
Results The combination of 267 and Dt resulted in increased
cytotoxic activity, as determined using an assay of metabolic
activity. Combinations of cisplatin, doxorubicin, vinorelbine,
paclitaxel, and trastuzumab produced antagonistic interactions.
Further endpoint analysis in cell lines with low Her2 levels
revealed that the 267/Dt combinations resulted in: a three-fold
decrease in concentration (dose) of 267 required to achieve
50% inhibition of P-AKT; and a dramatic disruption of normal
filamentous-actin cellular architecture. In contrast to Her2-
positive cell lines, three-fold higher concentrations of 267 were
required to achieve 50% inhibition of P-AKT when the drug was
267: QLT0267; AKT: protein kinase B; BSA: bovine serum albumin; CH-ILKBP: calponin homology-containing ILK-binding protein; CI: combination 
index; D: dose; DMEM: Dulbecco's modified eagle's medium; DRI: dose reduction index; Dt: docetaxel; ECM: extracellular matrix; ED: effective doses; 
EDTA: ethylenediaminetetraacetic acid; EMT: epithelial to mesenchymal transition; F-actin: filamentous actin; FA/fa: fraction affected; FBS: fetal 
bovine serum; fu: fraction unaffected; GFP: green fluorescent protein; GSK-3: glycogen synthase kinase 3; Her2: human epidermal growth factor 
receptor 2; ILK: integrin-linked kinase; LCC6: MDA MB435/LCC6; LCC6Her2: MDA MB435/LCC6Her2/neu; luc: luciferin; MEP: median effect 
method; MLC: myosin light chain; P-AKT: phosphorylated AKT (serine 473); PBS: phosphate buffered saline; PDK-1: phosphoinositide-dependent 
kinase 1; ROI: region of interest; Tz: trastuzumab; v/v: volume to volume; VEGF: vascular endothelial growth factor; w/v: weight to volume.Breast Cancer Research    Vol 11 No 3    Kalra et al.
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used in combination with Dt. In vivo studies focusing on low
Her2-expressing breast cancer cells (LCC6) implanted
orthotopically demonstrated that treatment with 267/Dt
engendered improved therapeutic effects when compared with
mice treated with either agent alone.
Conclusions The findings indicate that the 267/Dt drug
combination confers increased (synergistic) therapeutic efficacy
towards human breast cancer cells that express low levels of
Her2.
Introduction
Integrin-linked kinase (ILK), an intracellular serine/threonine
kinase, is a key signaling molecule expressed in most, if not all,
tissues, with high levels of expression in normal pancreatic,
cardiac and skeletal muscle tissues. Through interactions with
a diverse range of proteins including adapters such as partic-
ularly interesting Cys-His-rich protein (PINCH), calponin
homology-containing ILK-binding protein (CH-ILKBP), affixin
and paxillin, kinases such as integrin-linked kinase-associated
serine/threonine phosphatase 2C (ILKAP), protein kinase B
(AKT) and phosphoinositide-dependent kinase 1 (PDK-1), and
transmembrane receptors such as β1 and β3 integrins [1], ILK
is thought to play a key role in integrin and growth factor
receptor related signaling cascades [2,3]. For example, ILK
acts as a scaffold protein to allow for protein-complex forma-
tions connecting extracellular integrin signals to intracellular
actin cytoskeleton rearrangements through direct interaction
with the cytoplasmic domain of β1 integrin [4]. Cell extracellu-
lar matrix (ECM) adhesion complexes influence a vast number
of cellular processes including cellular morphology, migration,
proliferation, survival, and differentiation. Activation of down-
stream targets of ILK such as AKT [5], glycogen synthase
kinase 3 (GSK-3) [6], myosin light chain (MLC) [7], affixin [8]
and the cytoplasmic domain of β1 integrin [9], is associated
with signaling cascades known to regulate transcription of
genes involved in a diverse range of functions including: cell
survival, cell cycle progression, cell adhesion and spreading,
focal adhesion plaque formation, ECM modification, cell motil-
ity, and contractility [1,10].
Increased ILK expression and activity is found in association
with many cancer types including: breast, brain, prostate, pan-
creatic, colon, gastric, ovarian, and malignant melanomas
[4,11-16]. Further, there is mounting experimental evidence
indicating that ILK plays a pivotal role in many processes asso-
ciated with tumorigenesis. Enforced over-expression of ILK in
immortalized rat intestinal epithelial cells induces epithelial to
mesenchymal transition (EMT) and a transformed tumorigenic
phenotype that is, in part, linked to ILK-dependent inhibition of
E-cadherin expression and increased nuclear translocation of
β catenin. Over-expression and constitutive activation of ILK
leads to dysregulated growth and suppression of apoptosis
and anoikis [17,18]. With specific respect to breast cancer,
over-expression of ILK in mammary cells stimulates anchor-
age-independent cell growth, cell cycle progression, and
increased cyclin D and A expression in vitro [2,19]. Further-
more, mammary epithelial cells over-expressing ILK exhibit
hyperplasia and tumor formation in vivo. [4]. Further evidence
has indicated ILK might play a key role in VEGF-mediated
endothelial activation and angiogenesis [4,20].
Targeted inhibition of ILK in cancer cells by various strategies
can also lead to suppression of the AKT signaling pathway,
inhibition of cell cycle progression, reduced vascular endothe-
lial growth factor (VEGF) secretion in vitro, and reduced tumor
growth in vivo [21]. A number of pharmaceutically viable small-
molecule inhibitors of ILK have been developed and partially
characterized. From the K15792 class of the pharmacophor
family [22], some of these inhibitors were shown to effectively
inhibit cancer cell survival, growth [23] and invasion [24], and
induce apoptosis and cell-cycle arrest in vitro [25], as well as
inhibit tumor growth and angiogenesis in vivo [20]. Interest-
ingly, the most promising ILK inhibitor, QLT0267 (267), while
capable of eliciting pleiotropic effects in xenograft models of
glioma, was unfortunately shown to only delay, but not prevent,
tumor growth in vivo, even at doses as high as 200 mg/kg
[2,23]. Based on these findings, we speculate that optimal
therapeutic effects of 267 will only be realized using a combi-
nation therapeutic strategy.
Here we demonstrate on the basis of a cell viability assess-
ment determined using multiple breast cancer cell lines that
267 in combination docetaxel (Dt) interacted in a synergistic
manner (increased therapeutic benefit over single agents as
assessed by the median effect methodology developed by
Chou and Talalay [26]). Experimentations aimed to identify
underlying molecular mechanisms and additional drug-drug
interactions using multiple endpoint analyses, revealed in
breast cancer cells expressing low levels of Her2, beneficial
drug-drug interactions on the basis of endpoints measuring
AKT phosphorylation and F-actin cytoarchitecture. Using an
orthotopic model of breast cancer (low Her2), 267/Dt combi-
nations were found to exert enhanced therapeutic activity, as
demonstrated by significantly reduced tumor growth and
extended survival in mice treated with the combination com-
pared to the single agents.
Materials and methods
Chemicals
Cisplatin, doxorubicin, paclitaxil, Dt, vinorelbine, and trastuzu-
mab (Tz) were obtained from the British Columbia Cancer
Agency Pharmacy (Vancouver, BC, Canada) and 267 was a
generous gift from QLT Inc (Vancouver, BC, Canada). All other
chemicals, unless specified, were purchased from Sigma
Chemical Company (Oakville, Ontario, Canada). Dt was
reconstituted in 13% ethanol for a final concentration of 10Available online http://breast-cancer-research.com/content/11/3/R25
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mg/ml and Tz (Hoffman-La Roche, Mississauga, Ontario, Can-
ada) was reconstituted in PBS at a stock concentration of 21
mg/ml.
Cell-lines and culture
MCF-7, KPL-4, BT-474, MDA MB/468 and SKBR3 cells were
purchased from American Type Culture Collection (Manassas,
VA, USA). MDA-MB-435 (LCC6) estrogen receptor-negative
breast cancer cells [27] and MCF-7Her2 cells were generously
donated. LCC6Her2 cells, previously described by our group
[28], were generated by the stable transfection (neomycin
selection using G418) of plasmid DNA containing the Her2
gene driven by the cytomegalovirus promoter. LCC6 cells
were stably transfected using a lenti-virus system with the luci-
ferase gene and green fluorescent protein (GFP). Cells were
sorted by FLOW cytometry for GFP expression and selected
cells were used in the following experiments. Sorted cells
exhibited similar in vitro and in vivo growth rates as the paren-
tal LCC6 cell line. Additionally LCC6luc and parental LCC6
were equally sensitive to Dt.
The breast cancer origin of the LCC6 parental cell line, MDA-
MB-435, is controversial. Based on studies of Ross and col-
leagues [29] and Rae and colleagues [30] it has been sug-
gested that the MDA-MB-435 cell line is of a melanoma origin.
However, Sellappan and colleagues [31] have been able to
demonstrate that MDA-MB-435 cells can be induced to
express breast differentiation-specific proteins and secrete
milk lipids. Further, more recent studies of Neve and col-
leagues [32] have demonstrated that the MDA-MB-435 cell
line shares many molecular features with breast cancer cell
lines of breast epithelium origin. In studies from our laboratory
[28] using a LCC6 cell line permanently transfected with the
Her2 gene (LCC6Her2 cell line), we have been able to demon-
strate that the Her2-positive variant exhibit enhanced survival
under stress, overproduction of VEGF, activation of nuclear
factor (NF) κB and in vivo sensitivity to Tz (aka Herceptin™;
Hoffman-La Roche, Mississauga, Ontario, Canada); results
that are consistent with what is known about Her2-positive
breast cancer models. Thus, we believe it is justifiable to use
these cells as a model breast cancer cell line; particularly
when the results obtained using this cell line are confirmed
with other breast cancer cell lines.
LCC6, LCC6Her2, LCC6luc, KPL-4, BT-474, MDA MB/468,
MCF-7 and MCF-7Her2 cells were maintained in Dulbecco's
modified eagle's medium (DMEM)/high glucose supple-
mented with L-glutamine (2 mmol/L; DMEM and L-glutamine
from Stem Cell Technologies, Vancouver, BC, Canada) 5 mM
penicillin/streptomycin, and 10% FBS (Hyclone, Logan, UT,
USA). SKBR3 cells were maintained in McCoy's 5a medium
(fStem Cell Technologies, Vancouver, BC, Canada) supple-
mented with L-glutamine, 5 mM penicillin/streptomycin, and
10% FBS. All cells were maintained at 37°C and 5% carbon
dioxide in a humidified atmosphere.
Cell viability assays
Metabolic activity (measure of cell viability) of breast cancer
cell lines incubated in the presence of various therapeutic
agents was determined using Alamar Blue® assays (Medicorp
Inc. Montreal, QU, Canada) according to the manufacturer's
suggestions. Briefly, 6000 cells/well seeded in triplicate onto
96-well flat-bottom tissue culture plates (Techno Plastic Prod-
ucts AG, Trasadingen, Switzerland) were allowed to adhere to
the substratum for 24 hours under normal growth conditions
(37°C and 5% carbon dioxide in a humidified atmosphere).
Serial dilutions of individual drugs, 267/drug combinations
and vehicle controls diluted in appropriate cell culture medium
were then added to the wells and cells were grown for an addi-
tional 72 hours. To assess cell viability, cells were then incu-
bated with 10% resazurin solution for four hours at 37°C and
fluorescence was measured at 560/590 nm using an Optima
fluorescence plate reader (BMG Labtech, Durham, NC, USA).
Relative fluorescence determined from drug-treated cells was
normalized to fluorescence determined from control cells
(cells grown in presence of appropriate vehicle control alone)
and data is shown as percentage relative cell viability com-
pared with vehicle-treated control cells (100% viability, high-
est fluorescence). Background fluorescence was subtracted
from all samples and results of experiments conducted in trip-
licate are indicated (average ± standard deviation).
Drug combination effects – median effect principle
To determine whether various 267/drug combinations had
resulted in synergistic, antagonist, or additive effects, the
median effect principle (MEP) method of Chou and Talalay
was used to determine combination index (CI) values
[26,33,34]. Briefly, the MEP method is used to describe and
understand the relationship between a measured response
within a population of cells (fraction affected (fa) versus the
fraction unaffected (fu)) and the fraction of the dose (D)
required to achieve an effect level of 50% and is represented
by the formula:
- where Dm is the dose required to achieve a 50% effect level
and m is a coefficient indicating the sigmoidicity of the dose-
effect curve. The right side of the equation [(D/Dm)m] repre-
sents the dose, and the left side of the equation [fa/fu] repre-
sents the effect of the interaction. The CI can be calculated at
any effect level and the effect used can be derived on the basis
of different endpoints (e.g. cell viability, inhibition of VEGF
secretion, etc.). If CI is equal to one then the combination inter-
actions result in additive effects, if the CI is less than one the
combination interactions are considered synergistic, and if the
CI is greater than one the combination interactions are consid-
ered antagonistic.
To determine CI values, the commercially available program
CalcuSyn (Biosoft Ferguson, MO, USA) was used to calculate
ff D D a /( / ) um
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CI values for a broad range of effect levels and, on the basis of
this analysis, Fa versus CI plots were generated. CI values
were then used to estimate the dose reduction index (DRI) for
combination of drugs. The DRI estimates the extent to which
the dose of one or more agents in the combination can be
reduced to achieve effect levels that are comparable with
those achieved with single agents. Drug combinations that
acted synergistically can be identified as those that exhibited
significant dose reduction values (i.e. a given measured effect
will be observed at dose(s) significantly lower than expected
based on single agent activities).
VEGF expression
To determine whether a specified treatment influenced VEGF
expression, ELISA assays using Quantikine Human VEGF
Immunoassay kits (R&D Systems, Minneapolis, MN, USA)
were conducted according to manufacturer's suggestions.
Briefly, 6000 cells were seeded onto 96-well tissue culture
plates and allowed to adhere for 24 hours. Cells were then
grown in the presence of single agents or combinations of
drugs for 72 hours (as described above). The experiments
were completed in triplicate and repeated at least two times.
Supernatants were collected, combined, and then assayed for
the presence of secreted VEGF (specific for recombinant
human VEGF165 and recombinant human VEGF121) using the
Optima fluorescence plate reader (BMG Labtech, Durham
NC, USA). Results were normalized to total protein found in
supernatant and compared with standard curves determined
using VEGF standards provided in the kit. This assay accu-
rately measures VEGF levels between 9 pg/ml and 2000 pg/
ml.
Western blot analysis
Total protein lysates were prepared from cells incubated in the
presence of single drug, the drug combinations or vehicle con-
trols. Briefly, cells were rinsed with PBS, harvested from plates
with trypsin, and centrifuged at 1500 × g for five minutes. Cell
pellets were then re-suspended in lysis buffer (150 mmol/L
sodium chloride, 1% NP40, 0.5% sodium deoxycholate, 2.5
mmol/L EDTA, 0.1% SDS), Mini protease inhibitor cocktail
tablets (Roche Diagnostics, Mannheim, Germany), sheared
using 25-gauge needles, incubated on ice for 30 minutes, and
finally centrifuged at 10,000 × g for 10 minutes to remove
insoluble material. Protein concentrations were determined
from supernatant using the Bradford Method and approxi-
mately 75 μg of total protein from each sample were dena-
tured in loading buffer (Invitrogen, Burlington, ON, Canada) by
boiling for 10 minutes and loaded onto 10% SDS-PAGE. Pro-
teins separated by electrophoresis were transferred to Nitro-
cellulose membrane (Millipore, Bedford, MA, USA) and
blocked for one hour at room temperature in Odyssey blocking
buffer (Licor Biosciences, Lincoln, NB, USA). Membranes
were incubated at 4°C overnight in Odyssey blocking buffer
containing polyclonal anti-ILK, anti-AKT, anti-P-AKT or anti-
Her2 antibodies (1:1000 dilution; Cell Signalling Technology,
Beverly, MA, USA). Membranes were then washed three times
for five minutes with PBS-Tween (1% v/v) and incubated with
either anti-rabbit or mouse IRDYE (green) (Rockland, Gilberts-
ville, PA, USA) or anti-rabbit Alexa 680 (red) (Invitrogen,
Molecular probes, Burlington, ON, Canada) (1:10,000) for
one hour at room temperature and signals were detected and
quantified using the Odyssey Infrared Detection System and
associated software (Odyssey v1.2; Licor, Lincoln, NB, USA).
Background and input variation between samples were cor-
rected using signal intensities for negative control pixel noise
and actin band intensities, respectively. Data were expressed
as mean values ± standard deviation and parametric analysis
was performed using an unpaired Student t-test.
Immunofluorescence analysis
Cells grown on coverslips were rinsed with PBS (pH 7.4),
fixed using 2.5% paraformaldehyde (w/v) in PBS for 20 min-
utes at room temperature and permeabilized using 0.5%Triton
X-100 (v/v) in PBS for five minutes at room temperature. Cov-
erslips were then washed three times with PBS and incubated
for one hour in 2% BSA (w/v) in PBS to block non-specific
binding, washed three times in PBS, and then incubated with
phalloidin conjugated to Texas red (1:500) (Molecular Probes,
Eugene, OR, USA) for 20 minutes at room temperature. Nuclei
were stained using Hoechst nuclear stain (10 mg/ml) (Molec-
ular Probes, Eugene, OR, USA) (1:1000) for 15 minutes at
room temperature. Coverslips were rinsed once with double
distilled water and mounted to microscope slides using a 9:1
solution of glycerol and PBS (Air Products & Chemicals, Inc.,
Allentown, PA, USA). Images were viewed and captured using
a Leica CTR-mic UV fluorescent microscope (Wetzlar, Ger-
many) and a DC100 digital camera with Open Lab software
(Improvision, Lexington, MA, USA).
Tumor xenografts
All animal studies were conducted in accordance with institu-
tional (University of British Columbia) guidelines for humane
animal treatment and according to the current guidelines of
the Canadian Council of Animal Care. Mice were maintained
at 22°C in a 12-hour light and dark cycle with ad libitum
access to water and food. Two million LCC6luc cells were
injected into the mammary fat pad of female NCr nude mice
(Taconic, Oxnard, CA, USA) in a volume of 50 μL using a 28-
gauge needle. Tumor growth was monitored using an IVIS 200
non-invasive imaging system (Xenogen, Caliper Life Sciences,
MA, USA), and manually using callipers when tumor dimen-
sions exceeded 3 mm in length and width. Tumor volume
(mm3) estimated from length and width measurements were
calculated according to the equation length times width
squared divided by two with the length (mm) being the longer
axis of the tumor. Animal body weights were recorded every
Monday and Friday.Available online http://breast-cancer-research.com/content/11/3/R25
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In vivo imaging system
Imaging was performed once every seven days to monitor
tumor progression. LCC6luc tumor-bearing mice were injected
intraperitoneally with 500 μl D-luciferin (15 mg/ml) (Xenogen
Corp., Alameda, CA, USA). Mice were anesthetized using iso-
flurane and twenty minutes post intraperitoneally injection
mice were imaged. Photographic and luminescence images
were taken at exposure times of one, two, and five second(s)
and Xenogen IVIS® software was used to quantify non-satu-
rated bioluminescence in regions of interest (ROI). Light emis-
sion between 5.3067 × 106  and 2.2179 × 109  was
determined to contain tumor tissue while emissions below this
range were considered as background. Bioluminescence was
quantified as photons/second/cm2/steradian for each ROI.
Statistical analysis
All statistical data was collected using GraphPad InStat (San
Diego, CA, USA). One-way analysis of variance was per-
formed using standard error of the mean, mean and n and a
Tukey-Kramer Multiple Comparisons Test was used as the
post hoc test.
Results
Breast cancer cells treated with 267 exhibit dose-
dependent decreases in cell viability
To study whether inhibition of ILK causes reduced breast can-
cer cell viability, seven human breast cancer cell lines (BT474,
SKBR-3, KPL-4, MDA-MB/468, MCF-7, LCC6 and LCC6Her2)
were exposed to serial dilutions (ranging from 1 to 256 μM) of
the small molecule inhibitor of ILK, 267. As shown in Figure 1a,
all cell lines examined exhibited 267 dose-dependent
decreases in cell viability. Using the CalcuSyn™ program,
effective doses (ED) capable of eliciting a 10, 50, or 90%
decrease in cell viability were extrapolated from each dose
response curve and these data have been summarized in
Table 1. ED values showed some variation (ED50s ranging
from 10 to 71 μM) depending on the specific breast cancer
line examined. In general, slower growing breast cancer cells
(SKBR-3 and BT-474) appear less sensitive to 267 than faster
growing breast cancer cells (MCF-7 and LCC6).
Although one cannot completely rule out the possibility that
off-target ILK-independent, 267-mediated cellular effects
might influence cell viability, treatment with 267 did cause
dose dependent decreases in P-AKT levels, a key downstream
target of ILK. These data have been summarized in Figure 1b,
which provides the dose of 267 required to achieve 50%
reduction of P-AKT in each of the seven cell lines evaluated.
Cells were treated with eight different concentrations of 267
for eight hours and P-AKT levels in cell lysates were deter-
mined by western blot analysis as described in the Materials
and methods. Dose-response curves were generated and the
ED capable of eliciting a 50% decrease PAKT was extrapo-
lated from individual curves. KPL4 cells did not exhibit any
Figure 1
Breast cancer cells exhibit dose-dependent decrease in (a) cell viability and (b) P-AKT in response to increasing concentrations of the ILK small mol- ecule inhibitor, QLT0267 Breast cancer cells exhibit dose-dependent decrease in (a) cell viability and (b) P-AKT in response to increasing concentrations of the ILK small mol-
ecule inhibitor, QLT0267. (a) Seven breast cancer cell lines (LCC6, LCC6Her2, SKBR-3, KPL-4, BT-474, MBA-MB-468, and MCF-7) were treated 
with increasing doses (1 μm to 256 μM) of 267 for 72 hours and cell viability was evaluated using the AlamarBlue® assay. Percentage cell viability 
relative to control (untreated) cells are shown. Each data point represents the mean (± standard deviation) determined from three experiments done 
in triplicate. Treated cells were assessed for phosphorylated protein kinase B (P-AKT) using western blot analysis of protein lysates collected eight 
hours after treatment. (b) Western blot were analyzed using densitometry, dose-response curves were generated and analyzed using Calcusyn to 
determine the ED50 of 267 for PAKT suppression for each cell line. 267 = QLT0267; ILK = integrin-linked kinase.Breast Cancer Research    Vol 11 No 3    Kalra et al.
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reductions in P-AKT even at the highest dose tested (50 μM).
It is notable that suppression of P-AKT did not necessarily cor-
relate with the cell viability data. For example, SKBR3 cells
were quite sensitive to 267-mediated inhibition of P-AKT lev-
els, but were the least sensitive in terms of the cell viability
assessments as determined by Alamar Blue metabolic assay.
Combination of 267 with chemotherapeutic agents 
commonly used for treating breast cancer identifies 
synergistic interactions with docetaxel
For an initial screen of drug combination effects two of the
seven breast cancer cells (LCC6 and LCC6Her2) were treated
with 267 in combination with cisplatin, doxorubicin, paclitaxel,
vinorelbine, Dt, and Tz and cell viability was determined using
the Alamar Blue metabolic assay. The combination effects
were measured over a broad range of effective doses and the
results have been summarized in Table 2. Importantly, combi-
nations of 267 with Dt exhibited synergistic interactions at all
drug ratios examined. In contrast, combinations of 267 with
cisplatin, doxorubicin, paclitaxel, and vinorelbine exhibited
antagonistic interactions. Tz exhibited variable interactions
with 267, which appeared to be highly ratio dependent, a com-
mon feature associated with other drug combinations [35]. It
should be noted, because Tz exhibited little measurable activ-
ity under the in vitro assay conditions used, fixed drug ratios of
267 with Tz were defined using the ED50 value of 267 and the
maximum concentration of Tz that had been used in the single
agent assay (1 mg/ml).
As shown in Figure 2, comparisons of dose response curves
(cell viability) of LCC6 (Figure 2a) and LCC6Her2 (Figure 2b)
cells treated with 267 and Dt alone and in combination
showed that when used in combination there was a shift in the
dose-response curves to the left when the doses plotted for
the combination are defined by the most active agent in the
combination (Dt). Although statistically significant shifts in
dose-response curves can be indicative of synergistic interac-
tions, it is difficult to draw this conclusion on the basis of the
sigmoidal dose response curves alone. Thus the dose-
response data were analyzed using the MEP developed by
Chou [26,33] (see Materials and methods). Using the Cal-
cuSyn® program, CI values were estimated and these results
have been summarized in Figures 2c and 2d. The CI values for
267/Dt combinations were, in general, below 0.9 for both
Table 1
Effective doses at 10, 50 and 90% effect levels of QLT0267 in human breast tumour cell lines
Cell line Drug concentration range (μM) ED10 (μM) ED50 (μM) ED90 (μM)
MDA MB 435/LCC6 2.0 to 256.0 2.05 17.2 143.6
MDA MB 435/LCC6her2/neu 2.0 to 256.0 1.66 12.2 90.4
MDA MB 468 1.0 to 133.3 0.91 25.6 718.7
MCF-7 1.0 to 133.3 1.15 9.8 83.3
KPL-4 2.0 to 256.0 0.31 12.1 473.0
BT-474 2.0 to 256.0 29.8 70.9 168.2
SKBR-3 2.0 to 256.0 28.8 55.8 108.2
Effective doses (ED) values were calculated with Calcusyn software using the median effect principle defined by Chou and Talalay [26].
Table 2
Synergy, antagonism, and additivity in LCC6 and LCC6Her2 cells treated with QLT0267 in combination with several clinically 
relevant agents
Chemotherapeutic agent Drug concentration range QLT0267: Drug ratio (nM)1 Result2
Cisplatin 0.15 to 20.0 μM 1, 2, 4: 1 Antagonistic at all ratios
Doxorubicin 0.0625 to 2.0 μM 10, 20, 40: 1 Antagonistic at all ratios
Paclitaxel 0.313 to 15.0 nM 1000, 4000:1 Antagonistic at all ratios
Vinorelbine 0.0625 to 4.0 nM 10,000, 20,000, 40,000: 1 Antagonistic at all ratios
Docetaxel 0.125 to 1.0 nM 50,000, 95,000: 1 Synergistic at all ratios
Trastuzumab 3.1 × 10-7 to 1 mg/ml 50,000: 1 mg/ml Variable
1 Drug ratios were chosen based on effective dose values of single agent treatment.
2 Synergy is defined as a combination that exhibits combination index values of less then one at high affect levels over a minimum of four drug 
concentrations.Available online http://breast-cancer-research.com/content/11/3/R25
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Figure 2
Breast cancer cells treated with 267 and docetaxel combined at a fixed ratio and added at various concentrations exhibit synergistic effects based  on a measured cell viability endpoint Breast cancer cells treated with 267 and docetaxel combined at a fixed ratio and added at various concentrations exhibit synergistic effects based 
on a measured cell viability endpoint. (a) LCC6 and (b) LCC6Her2 cells were treated with increasing concentrations of 267, docetaxel (Dt) or 267 
and Dt combined at a fixed ratio (50 μm:1 nm). Percentage cell viability relative to control cells not treated with drugs (100% viable) are shown and 
each data point is the average (± standard deviation) of triplicate samples. Combination index (CI) values determined by Calcusyn from dose-
response curves of (c) LCC6 and (d) LCC6Her2 cells treated with 267/Dt combinations. Data points represent the average (± standard deviation) 
from triplicate experiments. CI values less than one are indicative of synergistic effects; CI values greater than one are indicative of antagonistic 
effects; and CI values equal to one are indicative of additive effects. Fraction affected (FA) is a measure of the determined effect (cytotoxicity as 
measured by an Alamar blue assay) and amount of drug to achieve a FA of 0.5 is referred as the ED50. (e) Mean CI values at ED50 for LCC6, 
LCC6Her2, MCF-7, MDA MB468, KPL-4, and SKBR-3 cells treated with 267 and Dt combined are shown and each data point represents the aver-
age (± standard deviation) from triplicate experiments.Breast Cancer Research    Vol 11 No 3    Kalra et al.
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LCC6 (Figure 2c) and LCC6Her2 (Figure 2d) treated cells, indi-
cating weak to strong synergistic interactions. Importantly, the
CI values were consistently below one over a broad range of
effective doses as define by the fraction affected (FA) value.
The combination of 267 and Dt was also evaluated in several
other breast cancer cell lines. CI values were calculated from
cell viability dose response curves. These data are summa-
rized in Figure 2e, which shows the CI values determined at
the ED50 (dose exhibiting 50% loss in cell viability relative to
untreated cells). The results indicate that the observed syner-
gistic interactions (defined by mean CI values < 0.9) are
achieved in at least five of the six cell lines tested (LCC6,
LCC6Her2, MCF-7, MDA MB468, and SKBR-3). For KPL-4
cells the calculated CI values were indicative of slightly antag-
onistic (mean CI of 1.4) interactions.
If drug combinations interact in a manner that result in synergy,
then the dose of each drug used in the combination to achieve
a specific measurable effect level will be substantially reduced
when compared with the dose needed to achieve the same
effect level when the drugs are given alone. This parameter
can be calculated and is defined by the DRI (refer to Materials
and methods). The DRI can be used to estimate the doses of
267 and Dt needed when used in combination to achieve a
defined effect level which can then be compared with the sin-
gle agent dose required to achieve this effect. Based on these
analyses, it was estimated that the concentration (dose) of
267 in the 267/Dt combination required to achieve an ED50
could be reduced by up to 3.6-fold in the LCC6 cell line (Fig-
ure 3a). 267 dose reductions were less remarkable in the
other cell lines evaluated; ranging from no change to a 30%
reduction. A similar analysis was completed for Dt (Figure 3b)
and it was estimated that the concentration (dose) of Dt in the
267/Dt combination required to achieve an ED50 could be
reduced in all cell lines by 2 to 25-fold when compared with Dt
alone. For example in SKBR3 cells the ED50 of Dt given alone
is 5 nM while in combination with 267 the ED50 of Dt
decreases to less than 1 nM.
267 and 267/Dt combination treatments cause dose-
dependent reduction in P-AKT levels estimated by 
western blot analysis
Western blot analysis was used to assess P-AKT (specifically
at serine 473) levels in LCC6 and LCC6Her2 cells treated with
increasing concentrations of 267 alone (Figure 4a), Dt alone
(Figure 4b), or 267 in combination with Dt (Figure 4c). In these
studies P-AKT (Ser473) was measured eight hours after addi-
tion of 267, a time point selected because no significant
changes in cell viability (as measured by dye exclusion) were
noted (even at the highest 267 dose used) yet significant
reductions in P-AKT (Ser473) were detectable as noted in the
representative western blots shown in Figure 4. P-AKT
(Ser473) levels were reduced in a dose-dependent manner
over the range of 267 concentrations evaluated in both LCC6
and LCC6Her2 cells (Figure 4a). Dt treatment alone was shown
to have little or no measurable effect on P-AKT (Ser473) levels
(Figure 4b). In cells treated with the 267/Dt there were signif-
icant reductions in P-AKT (Ser473) levels which were also
dose dependent (Figure 4c). None of the treatment strategies
Figure 3
The dose reduction index (DRI) calculated using the Calcusyn program  was used to estimate the ED50 of drugs (267 and/or docetaxel)  against the indicated cell lines The dose reduction index (DRI) calculated using the Calcusyn program 
was used to estimate the ED50 of drugs (267 and/or docetaxel) 
against the indicated cell lines. The DRI estimates the extent to which 
the dose of one or more agents in the combination can be reduced to 
achieve effect levels that are comparable with those achieved with sin-
gle agents. Black bars indicate the mean ED50 calculated for the drugs 
when added alone and the grey bars indicate the mean ED50 calcu-
lated for the drugs when used in combination. (a) ED50s for QLT0267 
(267); when used in combination to treat LCC6 cells the ED50 of 267 
can be reduced by 3.6-fold. (b) ED50s for docetaxel; the dose reduc-
tion index assessment for docetaxel (Dt) indicated that dose reductions 
of up to 27.5 fold (LCC6 cells) can be obtained.Available online http://breast-cancer-research.com/content/11/3/R25
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were shown to influence expression of total ILK or total AKT
where protein loading was verified using β-actin. P-AKT levels
from three independent experiments (as illustrated in Figures
4a to 4c) were qualitatively assessed by densitometry to esti-
mate the effective doses needed to achieve a defined effect
level represented by a FA value. As described above, these
data in turn, could be used to estimate the dose of 267
required to achieve a defined level of P-AKT (Ser473) sup-
pression when the drug was used alone or in combination with
Dt. These calculated values have been summarized in Figure
4d (LCC6) and 4e LCC6Her2). The results clearly demonstrate
that the combination acts differently in the Her2-positive cell
line when compared with the parental LCC6 cell line. More
specifically for LCC6 cells the dose of 267 required to achieve
a defined level of P-AKT (Ser473) suppression was substan-
tially reduced when Dt was present indicating that Dt potenti-
ates 267 mediated suppression of P-AKT (Ser473). For
example, the dose of 267 required to achieve 50% suppres-
sion of P-AKT (Ser473) (FA = 0.5) when used alone was cal-
culated to be 30 μM, while in combination with Dt the dose
required to achieve the same FA was reduced three-fold. In
contrast, the densitometry data indicated that for LCC6Her2
cells, the concentration of 267 required in combination with Dt
to achieve a defined effect (FA) on P-AKT (Ser473) inhibition
Figure 4
Dose response curves were generated for changes in P-AKT in LCC6 and LCC6Her2 cells after treatment with QLT0267, docetaxel, or a fixed ratio  combination of QLT0267 and docetaxel Dose response curves were generated for changes in P-AKT in LCC6 and LCC6Her2 cells after treatment with QLT0267, docetaxel, or a fixed ratio 
combination of QLT0267 and docetaxel. LCC6 and LCC6Her2 cells were treated for eight hours with increasing concentrations of QLT0267, 
docetaxel, or a fixed ratio combination of QLT0267 and docetaxel (50 μm:1 nm) to establish dose response curves based on an endpoint measuring 
suppression of P-AKT levels as determined by western blot analysis. Representative western blot images were collected using a fluorescence based 
imaging system (odyssey, Licor) where the colours (red or green) represent the secondary antibody used, show that increasing concentrations of (b) 
docetaxel (Dt) exerted no significant effect on the expression of integrin-linked kinase (ILK), protein kinase B (AKT), and phosphorylated protein 
kinase B (P-AKT) in either cell line. Treatment with increasing doses of (a) QLT0267 (267) alone or (c) in combination with Dt showed dose-
dependent decrease in P-AKT. Densitometry assessment of western blots (n = 3) were used to estimate treatment response relative to controls 
(taken to be 100% P-AKT levels) and the resulting data was then analyzed by Calcusyn to determine estimated DRI. The DRI was then used to esti-
mate the dose of 267 when used alone (black bars) or in combination with Dt (grey bars) needed to achieve a defined fraction affected (FA). The 
dose of drug required to achieve an FA of 0.5 is defined as the ED50 for the measured P-AKT suppression endpoint. The ED50 of 267 was about 
30 μM in the (d) LCC6 cell line, while in the presence of (e) Dt the 267 ED50 was about 11 μM. In LCC6Her2 cells, more 267 was required when 
used in combination to achieve FA similar to that of single agents. For example in the LCC6Her2 cells, the 267 ED50 when used alone was about 30 
μM, and this increased to 130 μM when 267 was used in combination with Dt.Breast Cancer Research    Vol 11 No 3    Kalra et al.
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was significantly higher than that required when 267 was used
as a single agent. For example, 30 μM 267 was required to
achieve an FA of 0.5 (ED50) when 267 was used alone; how-
ever, in the presence of Dt the concentration of 267 required
to achieve an FA of 0.5 was estimated to be 130 μM.
Differences in the combination effects due to Her2 over-
expression were confirmed using the MCF-7 and MCF-7Her2
cell lines, as summarized in the representative western blots
shown in Figure 5. Qualitative (densitometry) assessments of
the P-AKT (Ser473) western blot data (average of triplicate
experiments) have been presented as a value that is relative to
control (untreated) P-AKT levels (Ser473) and these are pro-
vided in brackets. The 267/Dt combination resulted in
enhanced P-AKT (Ser473) suppression compared with 267
alone when used to treat the parental cell lines (Figures 5b, d).
However, this combination effect was lost when tested in the
Her2 over-expressing cell lines, where the level of P-AKT
(Ser473) suppression was no better or even worse than when
267 was used alone (compare Figures 5c and 5e). This effect
is most notable in the LCC6Her2 cells where 267 caused a
92% reduction in P-AKT (relative to control) when used alone,
but only a 24% reduction when used in combination with Dt.
It should be noted that all four cell lines studies expressed sim-
ilar levels of ILK and AKT (Figure 5a) and treatment with 267
and Dt alone or in combination did not effect total ILK or AKT
levels as detected by western blot analysis.
267 and 267/Dt combinations inhibit VEGF secretion
We investigated whether 267 alone or in combination with Dt
could influence VEGF secretion in LCC6, LCC6Her2, MCF-7,
and MCF-7Her2 cells, an endpoint measured 72 hours after
drug addition. The 72-hour time point was selected because
VEGF levels in the media were highest at this time; however,
it can be suggested at this time point VEGF levels would be a
reflection of both direct effects of 267 on VEGF expression
and indirect effects due to 267 and/or Dt cytotoxicity as fewer
viable cells capable of producing VEGF would be present. For
this reason we focused on doses of 267 and Dt below that
Figure 5
Levels of P-AKT were measured in LCC6, LCC6Her2, MCF-7, and MCF- 7Her2 cells after treatment with a singles dose of QLT0267, docetaxel,  or a combination of QLT0267 and docetaxel Levels of P-AKT were measured in LCC6, LCC6Her2, MCF-7, and MCF-
7Her2 cells after treatment with a singles dose of QLT0267, docetaxel, 
or a combination of QLT0267 and docetaxel. (a) LCC6, LCC6Her2, 
MCF-7, and MCF-7Her2 cells express baseline levels of integrin-linked 
kinase (ILK), protein kinase B (AKT), and phosphorylated AKT (P-AKT). 
(b) LCC6, (c) LCC6Her2, (d) MCF-7, and (e) MCF-7Her2 cells were 
treated for eight hours QLT0267 (267) (42 μM), docetaxel (Dt) (1 nM), 
or the combination of 267 and Dt. Western blot analysis using a fluo-
rescence based imaging system (odyssey, Licor) shows that treatment 
with 267 and 267/Dt elicit considerable reductions in the level of P-
AKT relative to controls (untreated cells). Treatment with Dt had no 
effect on P-AKT levels. Reductions in P-AKT were not attributable to 
changes in the level of ILK or AKT. Band intensities for P-AKT were nor-
malized to actin then to untreated controls and changes in levels are 
indicated in the values provided just below the P-AKT band (n = 3).
Figure 6
Levels of secreted VEGF were measured in LCC6, LCC6Her2, MCF-7,  and MCF-7Her2 cells after treatment with a singles dose of QLT0267,  docetaxel, or a combination of QLT0267 and docetaxel Levels of secreted VEGF were measured in LCC6, LCC6Her2, MCF-7, 
and MCF-7Her2 cells after treatment with a singles dose of QLT0267, 
docetaxel, or a combination of QLT0267 and docetaxel. LCC6, 
LCC6Her2, MCF-7, and MCF-7Her2 were treated with 267 (10 μM), Dt 
(0.25 nM) or a combination of both for 72 hours. Conditioned media 
was collected subsequently assessed for vascular endothelial growth 
factor (VEGF) secretions using ELISA as described in the Materials 
and methods. All four cell lines assessed showed a decrease in VEGF 
secretion when treated with low doses of QLT0267 (267) alone or with 
the combination 267/docetaxel (Dt). Dt also moderately attenuated 
VEGF secretion in each cell line (n = 3).Available online http://breast-cancer-research.com/content/11/3/R25
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which caused 50% toxicity over the 72-hour incubation time.
The results, summarized in Figure 6, are consistent with previ-
ous publications and indicate that when LCC6, LCC6Her2, and
MCF-7 cells are treated with 267 there is a significant
decrease in VEGF secretion. This decrease was not observed
in the MCF-7Her2 cell line. Treatment of LCC6 and LCC6Her2
cells with 10 μM 267 resulted in an approximately 79% and
83% decrease in VEGF secretion, respectively. When Dt was
combined with 267, the decrease in VEGF secretion was
larger (92%) when the drugs were added in combination to
the LCC6Her2 cells. Conversely, when the drugs were used in
combination to treat the LCC6 cells the decrease in VEGF lev-
els in the media was 72%, an effect that was actually less then
what was observed when using 267 alone. It should be noted
that treatment with Dt (0.25 nM) was associated with a 56%
and a 40% decrease in VEGF levels relative to controls for the
LCC6 and LCC6Her2 cells, respectively. Thus the enhanced
effect observed when using 267/Dt combination against the
LCC6Her2 cells could be explained by the effects of the individ-
ual agents. This, however, is not the case for the LCC6 cells.
The effect of 267 on VEGF secreted by MCF-7 cells was sim-
ilar to that observed with the LCC6 cell line; 267 produced a
90% reduction in VEGF secretion when used alone and only
53% reduction when used in combination with Dt. Results
obtained with the MCF-7Her2 cell line suggest that significantly
higher doses of 267 (more than 21 μM) was required to see
changes in VEGF levels found in the media. However, when
MCF-7Her2 cells are treated with a combination of 267 (10 μM)
and Dt (0.25 nM) significant reductions in VEGF secretion
were seen.
267/Dt treatment causes disruption of normal F-actin 
cytoarchitecture and abnormal nuclear morphology
In addition to assessing how Dt influenced known or sus-
pected downstream effects of the action of 267 on ILK (P-AKT
levels, VEGF secretion), the influence of 267 on Dt-induced
changes in cytoarchitecture and nuclear morphology were
investigated eight hours after drug addition to the cells. The
drug doses used were 42 μM for 267 and 1 μM for Dt; dose
that are cytotoxic (Alamar Blue metabolic assay) after 72 hours
but exhibit no significant cytotoxicity at eight hours after drug
addition. As illustrated by the representative photomicro-
graphs in Figure 7, immunofluorescence based experimenta-
tion showed that untreated LCC6 (Figure 7a) and LCC6Her2
(Figure 7b) cells contained normal intact nuclei (blue color)
and typical F-actin cytoskeleton (red color) with distinct intra-
cellular organization and prominent stress fibers. LCC6 cells
treated with 267 alone (Figure 7e) showed an accumulation of
Figure 7
267/Dt treatment of LCC6, LCC6Her2, MCF-7, and MCF-7Her2 causes disruption of normal F-actin cytoarchitecture and abnormal nuclear morphol- ogy 267/Dt treatment of LCC6, LCC6Her2, MCF-7, and MCF-7Her2 causes disruption of normal F-actin cytoarchitecture and abnormal nuclear morphol-
ogy. LCC6, LCC6Her2, MCF-7, and MCF-7Her2 were treated for eight hours with 267 (42 μM), Dt (1 nM) or the combination of 267 and Dt. Subse-
quently, cells were fixed using paraformaldehyde, permeabilized, and stained for nuclear material using Hoechst and F-actin using Texas red 
conjugated phalloidin. Representative photomicrographs of (a to d) untreated cells or cells treated with (e to h) QLT0267 (267), (i to l) docetaxel 
(Dt) and (m to p) the combination of 267/Dt are shown, where blue represents the nucleus and red the F-actin microfilaments. Combination treat-
ment resulted in a distinct decrease in total F-actin staining, a change in actin organization, the appearance of apoptotic nuclear bodies (white 
arrows), as well as metaphase chromosomes suggestive of a cell cycle block in these cells.Breast Cancer Research    Vol 11 No 3    Kalra et al.
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F-actin at the cell periphery, while LCC6Her2 cells treated with
267 alone (Figure 7f) exhibited cytoplasmic actin distribution
and increased formation of focal adhesions at cell periphery.
As expected, Dt treatment alone in LCC6 and LCC6Her2 cells
caused significant degeneration of both F-actin microfilaments
(Figures 7i and 7j). Importantly, 267/Dt treated LCC6 and
LCC6Her2 cells (Figures 7k and 7l, respectively) showed more
pronounced reduction of F-actin, appearance of apoptotic
nuclear bodies (arrows), and metaphase chromosomes, sug-
gesting that 267/Dt combination in these cell types specifi-
cally inhibited cell cycle progression.
Untreated MCF-7 cells showed the typical cytoplasmic distri-
bution of F-actin slightly enriched at the cellular membrane and
lack stress fibers (Figure 7c). MCF-7 cells treated with 267
(Figure 7g) showed accumulation of F-actin at the cell periph-
ery and punctate cytoplasmic staining, although cells treated
with Dt alone (Figure 7k) showed decreased F-actin expres-
sion, loss of uniform expression, and increased punctate
areas. Images of MCF-7 cells treated with 267/Dt (Figure 7o)
were strikingly similar to those shown for LCC6 cells treated
with this combination; reflected by reduced F-actin distribu-
tion, appearance of apoptotic nuclear bodies (arrows), and
presence of metaphase chromosomes. Untreated MCF-7Her2
cells showed typical punctate and peripheral staining of F-
actin as well as large nuclei enriched localization of F-actin at
the cell membrane (Figure 7d). MCF-7Her2 cells treated with
267 alone showed cell rounding and enriched F-Actin at the
cell membrane (Figure 7h), while cells treated with Dt alone
showed trademark [36] F-actin rings, peripheral stress fibers,
and punctate cytoplasmic staining (Figure 7l). Finally MCF-
7Her2 cells treated with 267/Dt (Figure 7p) showed disorgan-
ized F-actin, with peripheral staining; however, in contrast to all
the other cell lines examined, only minor changes in nuclear
morphology were evident.
267/Dt combination therapy in vivo correlates with 
reduced tumor burden and extended survival in 
orthotopic LCC6 breast cancer tumor model
The results presented thus far indicate that combinations of
267 and Dt should provide improved therapeutic effects
based on several different therapeutically relevant endpoints
when used to treat breast cancers with low Her2 expression.
The results demonstrated that the combination effects are
more complicated in cell lines that over-express Her2 and that
for some endpoints measured (P-AKT) the data do not neces-
sarily support further development of the 267/Dt combination
for tumors that over-express Her2. Studies to be reported
elsewhere have been completed to better characterize the
effects of 267 and ILK inhibition in Her2 over-expressing cell
lines. Here, however, we determined whether the favourable
drug-drug interactions observed in vitro for the low Her2
expressing cells line could be recapitulated in vivo. 267 and
Dt alone and in combination were used to treat mice with
established LCC6luc tumors (LCC6 transfected with luciferase
as described in the Materials and methods). These tumors
were readily detectable in all mice 24 hours and seven days
post-implantation of 2 × 106 cells. Mice (n = 5, per treatment
strategy) were treated with: the vehicle controls used for both
267 (orally) and Dt (intravenously); 200 mg/kg 267 (QD once
daily for 28 days; orally); 10 mg/kg Dt (Q7D once weekly for
four weeks; intravenously); or 267 (200 mg/kg; orally)/Dt (5
mg/kg; intravenously). The 267 dose and schedule was
selected based on previous studies that showed effective
therapy in different human xenograft models [21,37]. The aim
of this study was to determine whether use of 267 (200 mg/
kg QD once daily for twenty eight days) in combination with Dt
might improve treatment outcomes. A suboptimal dose of Dt
(5 mg/kg) was administered using a Q7D once a week for four
weeks dose schedule in order for us to assess whether 267
contributed to improved outcomes in a combination setting.
The results of this in vivo efficacy study have been summarized
in Figure 8. Tumor growth was monitored using non-invasive
imaging (Figures 8a to 8i) using the IVIS 200 (Xenogen, Cali-
per Life Sciences, MA, USA) to image luciferase expressing
LCC6 cells and by external calliper measurements (Figure 8j).
Survival (Figure 8k) was determined based on the time in days
required for the mice to be terminated due to tumor ulceration
and/or the presence of tumors exhibiting volumes in excess of
500 mg.
Tumors in animals treated with 267 (Figure 8f), Dt (Figure 8g),
and 267/Dt (Figure 8i) all showed reduced total light emission
(luciferase expression) 22 days post-cell injection when com-
pared with vehicle-treated control mice (Figure 8e). Quantifi-
cation of total light flux (n = 5 mice per treatment, average ±
standard error, background subtracted; Figure 8i) demon-
strated tumor burden was significantly less in mice that had
received the combination treatment as compared with mice
treated with the vehicle control or 267 alone (P < 0.05). There
was a modest difference in tumor burden between Dt and
267/Dt-treated mice, but this difference was not statistically
significant. When tumor burden was measured using callipers,
the tumors from 267/Dt-treated mice were significantly smaller
compared with all other treatment groups, including mice
treated with Dt alone, (P < 0.05; Figure 8j). It is interesting to
note that close examination of the pattern of luciferase expres-
sion showed that tumors from 267-treated animals (alone or in
combination) exhibited dark regions in the center of the tumor
(for an example refer to Figure 8f, inset). These dark regions
may reflect regions of necrosis or alternatively could be a
result of treatment induced changes in tumor perfusion that
may alter luciferin delivery to the tumors.
Kaplan-Meir survival analysis (Figure 8k) based on survival
endpoints defined by tumor ulceration and/or tumor size (500
mg or larger) showed that the median survival time was 28
days (or 21 day post-treatment initiation) for untreated mice,
33 days (or 26 days post-treatment initiation) for mice treated
with 267, 31 days (or 24 days post-treatment initiation) forAvailable online http://breast-cancer-research.com/content/11/3/R25
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mice treated with Dt and more than 90 days (or > 83 days
post-treatment initiation) for mice treated with the 267/Dt
combination. In reference to the latter group, it should be note
that three out of five mice treated with 267/Dt combinations
were still alive at day 91, while mice from all other treatment
groups had been terminated due to tumor ulceration and/or a
tumor size of more than 500 mg.
Discussion
Although it is understood that ILK is an important therapeutic
target in cancer, the data summarized here (Figure 8) and else-
where suggest that an ILK inhibitor such as 267 given alone
will not achieve much more than a delay in tumor progression.
Lack of potent single-agent activity, when using in vivo tumor
growth as an efficacy measure, lends support to the belief that
Figure 8
267/Dt combination therapy in vivo correlates with reduced tumor burden and extended survival in orthotopic LCC6 breast cancer tumor model 267/Dt combination therapy in vivo correlates with reduced tumor burden and extended survival in orthotopic LCC6 breast cancer tumor model. 
Bioluminescent imaging of orthotopic LCC6 tumors are shown one day after treatment initiation and on day 22 after treatment initiation. The treat-
ment groups included (a and e) vehicle controls, (b and f) QLT0267 (267), (c and g) docetaxel (Dt), and the (d and h) combination of 267/Dt 
treated animals (doses indicated on graph). Total light emission from tumors in animals was visualized and quantified. (i) Animals treated with the 
combination showed lower total light flux than all other treatment groups. Animals treated with 267 exhibited tumors with darkened areas in the core 
(see inset in f as an example). Tumor size in treated animals was measured by callipers and these data were used to estimate the (j) tumor volumes. 
The combination of 267/Dt was significantly lower (***P < 0.005) then all other treatment groups analyzed. (k) Kaplan-Meier survival analysis of data 
defining survival endpoints based on tumor ulceration and/or tumors more than 0.5 g were used to determine median survival times. For animals 
treated with 267 (200 mg/kg) the median survival time was 33 days (26 days post-treatment initiation), animals treated with Dt (5 mg/kg) exhibited a 
median survival time of 31 days (24 days post-treatment initiation); and animals treated with the 267/Dt combination exhibited a median survival time 
of more than 90 days (83 days post-treatment initiation). In this group three out of five animals were alive at day 90, while no animals were alive for 
any other treatment group.Breast Cancer Research    Vol 11 No 3    Kalra et al.
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ILK inhibitors must be developed in the context of other thera-
peutics. A similar trend was exemplified by treatment regi-
ments incorporating Tz (Herceptin™), a therapy that targets
Her2-expressing tumors. Tz as a single agent exhibits little sig-
nificant activity, but when used in a combination setting it has
proved to be of significant therapeutic value [38]. The studies
described here, focused on identifying agents that would work
synergistically with QLT0267. We used cell-based screening
assays in order to assess whether drugs commonly used for
breast cancer could be combined with 267 to achieve better
then expected therapeutic results. For these studies a fixed-
drug ratio experimental design was used where drug-drug
interactions were determined using at least three different
drug-drug ratios applied over a broad range of effective doses
(Table 2). We show for the first time that combination of 267/
Dt appeared to interact in a manner that results in synergy.
Drug-drug interactions were measured by use of the median
effect method of Chou and Talalay [26] and were initially
determined on the basis of a therapeutic endpoint measuring
metabolic activity (Alamar Blue assay). Synergy was observed
over a broad range of effective dose and was measured in five
out of six breast cancer cell lines tested (Figure 2), regardless
of Her2 status. Although limited to results obtained with the
two cell lines used for the broad combination screen (LCC6
and LCC6Her2) it is interesting to note that the 267/Dt combi-
nation was synergistic while combinations of 267 with paclit-
axel and vinorelbine appeared antagonistic. This would
suggest that the mechanism(s) promoting synergy may not
involve microtubules in general. It has been suggested that Dt
is more effective in treatment of breast cancer than paclitaxel
[39] and in addition to its influence on microtubule assembly
that culminates in a general cytotoxic response, Dt activity has
been linked to increased activation of the apoptotic program
and to changes of apoptotic marker expression [40-43]. It may
be these additional activities of Dt that combine with 267 to
produce enhanced therapeutic effects.
It was important to demonstrate that the individual drugs within
the 267/Dt combination exert benefits consistent with their
individual mechanisms of action. For example, 267 activity can
be linked to measured changes in P-AKT (ser473) levels and
VEGF while Dt activity can be assessed by drug-mediated
changes in cell architecture. ILK inhibition by 267 engenders
dose dependent decreases in levels of P-AKT (Figures 1b, 4
and 5) and when 267 is added as a single agent it can inhibit
VEGF secretion (Figure 6). Perhaps unexpectedly, single-
agent 267 treatment also caused changes in cytoarchitecture
and nuclear morphometry (Figure 7). This effect of 267 has not
be reported previously, however, studies have provided evi-
dence that ILK plays a role in cytoskeletal arrangement of actin
through the regulation of proteins such as Rac and Cdc42
[9,44,45]. Furthermore, siRNA mediated ILK silencing
resulted in diminished cell spreading and actin cytoskeleton
reorganization; results that help to explain ILK's role in the reg-
ulation of cancer cell motility and invasiveness [46]. Recent
evidence indicates a role for ILK in regulation of mitotic spindle
organization [47]. When this information is considered in light
of the activity of Dt, one can speculate about the mechanism
that may be promoting synergy when Dt is used in combination
with 267. Studies have shown that cells treated with Dt exhibit
a reorganization of the microfilament network [36], disturbed
microtubule structures, less F-actin stress fiber formation,
decreased activation of Rac1/Cdc42, reduced cell motility,
and an inhibition of angiogenesis [48]. When considering the
primary effect of Dt on the microtubule cytoskeleton of cancer
cells, and based on the results summarized here it can be sug-
gested that the combination of Dt and 267 may result in syn-
ergistic changes in tubulin, F-actin organization, and nuclear
degeneration during apoptosis.
As indicated above, inhibition of ILK by 267 was expected to
cause a decrease in P-AKT at serine 473. However, the effect
of Dt on AKT has not been well studied. Studies have sug-
gested that Dt can suppress the phosphorylation of AKT in
lymphoma cell lines [49] and lung carcinoma [50]. Others
have suggested that the AKT pathway can be activated by Dt
[51]. As shown in Figure 4, results obtained in several breast
cancer cell lines indicate that Dt added at doses of up to 1 nM
exerted no significant effect on P-AKT levels after an eight-
hour exposure. Importantly, Dt potentiates the effect of 267 on
P-AKT levels, at least in LCC6 and MCF-7 cell lines (Figures
4 and 5). Interestingly, this beneficial combination effect was
not observed in the Her2 transfected variants of these cell
lines, suggesting that phosphorylation of AKT does not play a
role in the enhanced cytototoxicity seen when 267 is com-
bined with Dt to treat the Her2 over-expressing cells.
It has also been established that one of the beneficial thera-
peutic effects of 267 is associated with its ability to inhibit
VEGF secretion. More specifically, it has been reported that
integrins cooperate with the VEGF receptors to promote ang-
iogenesis in vascular endothelial cells [52] and other studies
indicate that ILK and PI3-kinase are involved in VEGF signaling
pathways [53]. Although not well studied, it has been sug-
gested that Dt can influence vascularization in vivo in a fashion
that is related to VEGF signaling. More specifically, Murtagh
and Schwartz [54] have recently demonstrated that Dt can
prevent VEGF-induced phosphorylation of focal adhesion
kinase, Akt and endothelial nitric oxide synthase, effects that
may be mediated by Dt mediated dissociation of Hsp90 from
tubulin and subsequent Hsp90 degradation by ubiquination.
Thus, it could be speculated that combinations of 267 and Dt
would be of particular interest in the context of VEGF-induced
tumor vascularization; where 267 would suppress VEGF pro-
duction and Dt would mitigate signaling through any remaining
VEGF. However, preliminary in vitro studies summarized in
Figure 6 suggest in the cell lines that express low levels of
Her2 that the 267/Dt combination was less effective at inhib-
iting VEGF secretion then when 267 was used alone. Similar
to the P-AKT (Ser473) results, when using VEGF secretion asAvailable online http://breast-cancer-research.com/content/11/3/R25
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an endpoint, the results obtained in the Her2 over-expressing
cell lines differed from those obtained with cells that express
low Her2 levels.
On the basis of VEGF secretion and P-AKT (Ser473) data we
can conclude that the 267/Dt drug combination effects were
dependent on Her2 expression. These differences encour-
aged us to assess the effect of 267 on Her2 signalling in the
Her2-positive cell lines. Although not reported here, these
studies demonstrated that 267 treatment induced a dose-
dependent decrease in Her2 levels; an effect that could also
be obtained when using siRNA to silence ILK. This unex-
pected effect of 267 on Her2-positive cell lines complicated
the interpretation of results in these cells and for this reason
the in vivo studies reported here focused on mice bearing
orthotopically transplanted LCC6 cells, which do not express
detectable levels of Her2.
Conclusions
This in vivo study provided evidence supportive of the benefi-
cial therapeutic effects of the 267/Dt combination LCC6
tumors (Figure 8) and suggest that further studies are war-
ranted to address development of this combinations and the
factors that may influence treatment outcomes; factors that
include drug dose, schedule and sequencing as well as an
assessment of therapeutic response in vivo that also includes
multiple endpoints (e.g. tumor cell proliferation and death as
well as tumor vascularization).
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